New Study Shows Rigel's (RIGL) Tavalisse May Have a Role in Treating COVID-19 Acute Lung Injury - Citi
Tweet Send to a Friend
Citi analyst Yigal Nochomovitz reiterated a Buy rating and $7.00 price target on Rigel Pharmaceuticals (NASDAQ: RIGL) noting new evidence ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
